Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE IMMUNE-SYSTEM RESPONSE DURING DEVELOPMENT AND PROGRESSION OF CARCINOGEN-INDUCED RAT MAMMARY-TUMORS - PREVENTION OF TUMOR-GROWTH AND RESTORATION OF IMMUNE-SYSTEM RESPONSIVENESS BY THYMOPENTIN
Autore:
GALLO F; MORALE MC; SAMBATARO D; FARINELLA Z; SCAPAGNINI U; MARCHETTI B;
Indirizzi:
UNIV CATANIA,SCH MED,DEPT PHARMACOL,6 A DORIA I-95125 CATANIA ITALY UNIV CATANIA,SCH MED,DEPT PHARMACOL I-95125 CATANIA ITALY
Titolo Testata:
Breast cancer research and treatment
fascicolo: 3, volume: 27, anno: 1993,
pagine: 221 - 237
SICI:
0167-6806(1993)27:3<221:TIRDDA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-ADRENERGIC RECEPTORS; MEDIATED CYTOTOXICITY; DOWN-REGULATION; LHRH RECEPTORS; BEARING MICE; LYMPHOCYTE; THYMUS; ADENOCARCINOMA; SUSCEPTIBILITY; DETERMINANT;
Keywords:
DIMETHYLBENZ(A)ANTHRACENE; MAMMARY TUMORS; THYMUS GLAND; THYMIC HORMONES; THYMOPENTIN; CELL-MEDIATED IMMUNITY; HUMORAL IMMUNE RESPONSE; LYMPHOCYTE SUBSETS; INTERLEUKIN 2 RECEPTORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
52
Recensione:
Indirizzi per estratti:
Citazione:
F. Gallo et al., "THE IMMUNE-SYSTEM RESPONSE DURING DEVELOPMENT AND PROGRESSION OF CARCINOGEN-INDUCED RAT MAMMARY-TUMORS - PREVENTION OF TUMOR-GROWTH AND RESTORATION OF IMMUNE-SYSTEM RESPONSIVENESS BY THYMOPENTIN", Breast cancer research and treatment, 27(3), 1993, pp. 221-237

Abstract

A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependentmitogens, antibody production, lymphocyte subset phenotyping, interleukin 2 receptor expression in resting and activated lymphocytes, thymus morphology and morphometry), were correlated with tumor appearance and growth at different (- 7, 0, + 15, + 30, + 60, + 90, and + 120 days) time intervals after intragastric administration of DMBA, in the absence or the presence of a concomitant treatment with the thymic pentapeptide thymopentin (TP5). A profound and time-dependent immunosuppression characterized the treatment with the carcinogen. Both cell-mediated and humoral immune responses showed a 50% inhibition 2 weeks after DMBA administration, with a peak after 30 days, followed by a plateau until 120 days of observation. The mechanism responsible for reduced ability of thymocytes and splenocytes to respond to both Con-A and PHA was explained by the significant inhibition of one of the key steps of T cell activation, namely the expression of IL-2 receptor in lymphocytes from DMBA-treated animals. The flow cytometric analysis of lymphocyte subpopulations revealed an important reduction in the overall populations of thymocytes and splenocytes. At the thymus gland level, a dramatic reduction of double positive CD4+CD8+ and a decrease of CD4+CD8-and CD4-CD8+ were observed, together with a marked atrophy of the thymic cortex, and impairment of the thymic microenvironment. One hundredand twenty days after DMBA administration, approximately 60 to 70% ofthe animals developed tumors with a mean tumor surface area of 2.88 +/- 0.86 cm(2), and a number of 2.44 +/- 1.0. Treatment with TP5 (100 ng/animal, three times a week, starting a week before DMBA), produced specific effects on different immune compartments and tumoral growth, characterized by a significant reversal of immune depression with a stimulatory effect measured on lymphoproliferative assays, lymphocyte subset distribution, and IL-2 receptor expression. Moreover, thymic atrophy was almost completely prevented in TP5 treated animals. Of major interest, a significant delay in the appearance and growth of tumors wasobserved in TP5 treated rats. When DMBA-treated animals were followedfor the entire observation period (0-120 days) and the immune responsiveness correlated according to tumor progression, stability, or regression, a positive correlation was calculated between the degree of immune system depression and the individual rate of tumor growth; in TP5-treated rats the majority of the tumors were static or regressing tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:31:54